國家衛生研究院 NHRI:Item 3990099045/7937
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 927309      在线人数 : 694
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7937


    题名: Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors
    作者: Chen, L;Shiah, H;Chao, T;Hsieh, RK;Chen, G;Chang, J;Yeh, G
    贡献者: National Institute of Cancer Research
    摘要: Background: PEP02 is a novel nanoparticle liposome formulation of irinotecan (CPT-11) that has improved PK and tumor biodistribution of CPT-11 and its active metabolite-SN38 with encouraging safety and tumor response in preclinical studies and a single-agent phase I study. The study is to define the DLT, MTD, and PK of PEP02 when in combination with high-dose fluorouracil/leucovorin (HDFL) in patients (pt) with advanced solid tumors. Methods: Pts who had failed to standard chemotherapy, ECOG PS 0-1 and adequate organ functions, no prior CPT-11, were eligible. PEP02 was given as 90 mins i.v. infusion on D1 in combination with 24-hr infusion of 5FU (2,000 mg/m2)/ LV (200 mg/m2) on D1 and D8, every 3 weeks. Cohorts of 3-6 pts were treated at 60, 80, 100, and 120 mg/m2. PK and PGx samples were collected. Results: A total of 16 pts were enrolled, with 3, 6, 5, and 2 at 60, 80, 100, and 120 mg/m2. DLTs were observed in 4 pts, including 2 each at 100 and 120 mg/m2 dose levels. DLTs were mainly G3 diarrhea and G4 hematologic toxicities. MTD was determined as 80 mg/m2. Grade 3 or above adverse events at the MTD dose and all dose levels were 10.6% and 18.4%, respectively. The PK of total CPT-11 after PEP02 (at 80 mg/m2) in combination with HDFL was characterized by low clearance (mean = 116.4 mL/m2/hr) and small volume of distribution (mean = 2.93 L/m2, similar to plasma volume) as did of PEP02 monotherapy study. Compared to the PK of SN-38 after 250 mg/m2 of CPT-11 (in combination with capecitabine, Ann Oncol 2005; 16: 1123-32), the Cmax after 80 mg/m2 of PEP02 was lower (7.98 ± 4.39 vs 62.0 ± 37.4 ng/mL), but the AUC0 t was similar (354.77 ± 145.35 vs 396 ± 247 ngxh/mL). The correlation of UGT1A family with PK and toxicity was not observed. However, the only subject with the coexistence of two variants of UGT1A1*6 and *28 had higher dose-normalized AUCSN-38and experienced DLT. The best response of 15 evaluable pts was PR in 2 (gastric cancer and breast cancer) and SD in 9. Conclusions: The MTD of PEP02 in combination with HDFL given every-3-week is 80 mg/m2. The observation of tumor response in two heavily pre-treated patients suggests the combination deserves further exploration in advanced solid tumor patients who are refractory to standard therapy.
    日期: 2010-05
    關聯: Journal of Clinical Oncology. 2010 May;28(15):Abstract Number e13024.
    Link to: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/e13024
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000208852000267
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈